<DOC>
	<DOC>NCT01615354</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled, cross-over study will assess the effect of aleglitazar on the pharmacokinetics and pharmacodynamics on MicrogynonÂ® in healthy volunteers. Volunteers will receive multiple oral doses of aleglitazar in one period; in the other period volunteers will receive placebo.</brief_summary>
	<brief_title>A Study of Aleglitazar in Combination With Oral Contraceptive Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Healthy female volunteer, 18 to 45 years of age Body mass index (BMI) between 18.0 and 29.9 kg/m2 Body weight at least 55.0 kg Nonpregnant, not lactating and not planning pregnancy from screening to 3 months after the last dose of study treatment Nonsmoker for at least 3 months Currently active gynecological disorder History of amenorrhea within the previous 3 years Known or suspected history of estrogendependent neoplasia or sex hormonedependent malignant tumors Use of steroid hormonecontaining intrauterine device (IUD) or progesteronerelease IUD contraceptive within 3 months to screening. History of clinically significant disease that could jeopardize the volunteer safety in the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>